Cell and Gene Regulatory
-
The Hidden Risks Of Novel Capsid Generation (And How To Avoid Them)
11/18/2026
Engineered viral capsids can create manufacturing and analytical challenges. Learn strategies to identify risks early, develop controls, and keep gene therapy programs on track.
-
Analytical Strategy As A Competitive Advantage In Biologics Development
11/16/2026
Distinguish meaningful biologic changes from normal variability with analytical strategies that strengthen process understanding, improve decisions, and uncover risks earlier.
-
Integrating Analytical And Process Development For Cell Therapies
11/12/2026
Integrating process development, RNA sequencing, and flow cytometry guides media selection, tracks phenotypic shifts, and accelerates cell therapy commercialization and regulatory progress.
-
Why CMC Must Shape Critical Decisions Early In Development
11/11/2026
Case studies reveal the gap between research progress and clinical readiness. In these stories, earlier CMC involvement might have saved resources and staved off delays.
-
Why Bridging Cleanroom Infrastructure And Process Equipment Design Is Critical
11/10/2026
Conflicting regulations and poor design can misalign cleanroom mechanical systems with process equipment, creating contamination risks, compromising product quality, and delaying facility startup.
-
The Latest Updates For Sterile Filtration And Single-Use Assemblies
11/5/2026
Revised sterile manufacturing rules shift attention from isolated compliance tasks to evidence that sterility holds across filtration, aseptic connections, single-use systems, and suppliers.
-
Rethinking Commercial Viability in CGT with Treehill Partners' Ali Pashazadeh
11/5/2026
Episode 141 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Ali Pashazadeh, Founder, Chairman, and CEO of Treehill Partners, about the manufacturing challenges that continue to limit cell and gene therapy development.
-
DGOF Readiness Package For Research Institutions
11/4/2026
Our DGOF Readiness Package provides a coordinated set of templates that assist you in achieving compliance. It includes an institutional policy, an IRE charter, and a standard operating procedure.
-
What Europe's Draft Annex 22 Actually Asks Of Human Oversight Of AI
11/4/2026
The European Commission and the Pharmaceutical Inspection Co-operation Scheme (PIC/S) consulted on draft Annex 22, Artificial Intelligence. Here's what you should know.
-
The EU Overhauls Pharma Laws: What You Need To Know
11/2/2026
On Sept. 18, the Council of the EU published the almost-final text of a major overhaul of the EU pharmaceutical laws. The final binding text is expected to be published very soon.